HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lawrence Blonde Selected Research

Nausea

11/2020Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo.
11/2019Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
5/2015Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.
6/2010Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents.
7/2009Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Lawrence Blonde Research Topics

Disease

86Type 2 Diabetes Mellitus (MODY)
05/2023 - 01/2002
25Hypoglycemia (Reactive Hypoglycemia)
10/2022 - 04/2004
15Body Weight (Weight, Body)
10/2022 - 05/2008
12Weight Loss (Weight Reduction)
05/2023 - 11/2006
11Weight Gain
01/2021 - 12/2004
8Cardiovascular Diseases (Cardiovascular Disease)
05/2023 - 10/2012
6Hypertension (High Blood Pressure)
05/2023 - 08/2005
6Dyslipidemias (Dyslipidemia)
05/2023 - 08/2005
5Heart Failure
01/2022 - 10/2012
5Nausea
11/2020 - 07/2009
5Diabetes Complications
01/2012 - 10/2002
5Hyperglycemia
03/2010 - 04/2003
4Diabetes Mellitus
05/2023 - 11/2006
4Insulin Resistance
10/2021 - 10/2002
3Prediabetic State (Prediabetes)
05/2023 - 11/2011
3Type 1 Diabetes Mellitus (Autoimmune Diabetes)
10/2022 - 12/2004
2Obesity
05/2023 - 10/2022
2Overweight
05/2023 - 11/2006
2Kidney Diseases (Kidney Disease)
10/2022 - 01/2022
2Neoplasms (Cancer)
10/2022 - 11/2013
2Body Weight Changes
11/2020 - 01/2020
2Vomiting
11/2019 - 05/2015
2Stroke (Strokes)
01/2015 - 10/2012
2Metabolic Diseases (Metabolic Disease)
01/2015 - 11/2006
2Myocardial Infarction
01/2015 - 10/2012
1Infertility (Sterility)
10/2022
1Diabetic Neuropathies (Diabetic Neuropathy)
10/2022
1Cardiogenic Shock
05/2015
1Pneumonia (Pneumonitis)
05/2015
1Ventricular Fibrillation
05/2015
1Fibrosis (Cirrhosis)
10/2014
1Chronic Renal Insufficiency
10/2014
1Sepsis (Septicemia)
10/2014
1Unstable Angina
10/2012

Drug/Important Bio-Agent (IBA)

41Insulin (Novolin)FDA Link
05/2023 - 10/2004
23Glucose (Dextrose)FDA LinkGeneric
05/2023 - 10/2002
22Hypoglycemic Agents (Hypoglycemics)IBA
05/2023 - 04/2004
16Insulin Glargine (Lantus)FDA Link
01/2022 - 04/2013
15Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
10/2022 - 10/2002
14Glucagon-Like Peptide 1 (GLP 1)IBA
10/2022 - 02/2009
13Glucagon-Like Peptide-1 ReceptorIBA
01/2021 - 07/2009
12LiraglutideFDA Link
10/2021 - 02/2009
11CanagliflozinIBA
01/2021 - 01/2014
11Metformin (Glucophage)FDA LinkGeneric
01/2021 - 04/2004
9SodiumIBA
01/2022 - 05/2014
9Blood Glucose (Blood Sugar)IBA
11/2020 - 01/2002
8lixisenatideIBA
01/2022 - 01/2017
7Glucagon-Like Peptide-1 Receptor AgonistsIBA
01/2022 - 12/2009
6Exenatide (Byetta)FDA Link
11/2019 - 07/2009
6LipidsIBA
08/2018 - 01/2005
5SymportersIBA
01/2021 - 04/2015
5Sitagliptin Phosphate (Januvia)FDA Link
11/2020 - 01/2013
4Hemoglobins (Hemoglobin)IBA
06/2021 - 11/2008
4insulin degludecIBA
01/2021 - 04/2013
4glimepiride (Amarel)FDA LinkGeneric
05/2016 - 02/2009
4oxidized low density lipoproteinIBA
11/2015 - 01/2014
4Bromocriptine (Parlodel)FDA LinkGeneric
01/2015 - 11/2011
3Sodium-Glucose Transporter 2 InhibitorsIBA
01/2021 - 05/2014
3dulaglutideIBA
11/2019 - 05/2015
3InsulinsIBA
11/2019 - 05/2014
3LDL CholesterolIBA
11/2015 - 01/2014
3Insulin Lispro (Humalog)FDA Link
05/2015 - 05/2014
3IncretinsIBA
11/2011 - 09/2006
2semaglutideIBA
10/2022 - 11/2020
2empagliflozinIBA
01/2021 - 11/2020
2dapagliflozinIBA
01/2021 - 01/2018
2IDegLiraIBA
11/2020 - 04/2016
2rGLP-1 proteinIBA
11/2019 - 01/2017
2Sodium-Glucose Transport ProteinsIBA
11/2019 - 01/2014
2ThiazolidinedionesIBA
01/2018 - 10/2002
2CholesterolIBA
02/2015 - 01/2012
2Triglycerides (Triacylglycerol)IBA
02/2015 - 01/2013
2Dopamine D2 Receptors (Dopamine D2 Receptor)IBA
01/2015 - 10/2012
2Protamines (Protamine Sulfate)FDA Link
05/2014 - 05/2014
2Nonesterified Fatty Acids (NEFA)IBA
01/2013 - 11/2006
2Rosiglitazone (Avandia)FDA Link
07/2009 - 02/2009
1VaccinesIBA
05/2023
1Peptides (Polypeptides)IBA
10/2022
1CreatinineIBA
06/2021
1Pioglitazone (Actos)FDA Link
11/2019
1omega-Chloroacetophenone (Mace)IBA
08/2018
1Insulin Detemir (Levemir)FDA Link
01/2018
1Urea (Carbamide)FDA LinkGeneric
01/2016
1HDL CholesterolIBA
11/2015
1EnzymesIBA
02/2015
1SympatholyticsIBA
01/2015
1ORALIT (ORS)IBA
10/2014
1Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA
05/2014
1Glucagon-Like Peptides (Enteroglucagon)IBA
05/2014
1Isophane Insulin (NPH Insulin)FDA Link
05/2014
1Dipeptidyl-Peptidase IV InhibitorsIBA
05/2014
1Human Isophane InsulinFDA Link
11/2013
1SecretagoguesIBA
11/2011

Therapy/Procedure

37Therapeutics
10/2022 - 10/2002
25Glycemic Control
05/2023 - 01/2002
4Injections
11/2020 - 10/2004
3Drug Therapy (Chemotherapy)
10/2022 - 03/2010
2Nutrition Therapy (Medical Nutrition Therapy)
03/2010 - 11/2006
1Bariatric Surgery
10/2022
1Length of Stay
10/2014